JLJean-François Laes

Jean-François Laes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jean-François Laes has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The clinical impact of using complex molecular profiling strategies in routine oncology practice

    by Jean-François Laes, Philippe Aftimos, Philippe Barthelemy, Joaquim Bellmunt, Guy Berchem, Carlos Camps, Ramón de Las Peñas, Ana Finzel, Jesús García-Foncillas, Petteri Hervonen, et al.

    The clinical impact of using complex molecular profiling strategies in routine oncology practice The clinical impact of using complex molecular profiling strategies in routine oncology practice


  • Open Access

    Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN

    by Jean-François Laes, Sebastien Sauvage, Gregori Ghitti

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jean-François Laes1, Sebastien Sauvage1 and Gregori Ghitti1 1OncoDNA SA, 6041 Gosselies, Belgium Correspondence to: Jean-François Laes, email: jf.laes@oncodna.com Keywords: cancer, biomarker, tumor stratification, mTor activation, PIK3CA activation and PTEN loss Received: August 16, 2016 Accepted: September 01, 2017 Published: September 28, 2017 ABSTRACT The mechanistic target of the rapamycin (mTOR) pathway is frequently activated in human cancers. Our objective was to evaluate relationships between mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN in solid-tumor biopsies from a broad selection of cancer types. Formalin-fixed paraffin-embedded (FFPE) tumor samples were analyzed by immunohistochemistry (IHC) and next-generation sequencing (NGS). TOR-pathway activation was identified by expression (by IHC) of the downstream effector p-4E-BP1. Activating PIK3CA mutations and null PTEN mutations were identified by NGS, and for PTEN, confirmed by IHC. Overall, mTOR-pathway activation was identified in 444/538 (83%) samples representing 40 different cancer types. Functional mutations in either or both PIK3CA and PTEN genes were identified in 173/538 (32%) samples. PIK3CA mutations were identified in 60/538 (11%) samples, PTEN mutations were identified in 155/538 (29%) samples and mutations in both PIK3CA and PTEN were identified in 18/538 (3%) samples. Overall, mTOR-pathway activation was not significantly associated with the PIK3CA and PTEN genotypes. However, all 18 samples with both PIK3CA and PTEN mutations also displayed mTOR-pathway activation (χ2 p=0.0471). Also, out of a total of 95 breast cancer samples, there were 5 breast-cancer samples which did not have mTOR-pathway activation, and all 5 (100%) of these had PIK3CA and PTEN mutations compared to 51/90 (57%) in the breast-cancer samples with mTOR-pathway activation (χ2 p=0.0134). Finally, the percentages of PIK3CA mutations were higher in colorectal-cancer samples which had mTOR-pathway activation (9/27, 33%) than in colorectal-cancer samples without mTOR-pathway activation (6/44; 14%; χ2 p=0.0484). Therefore, tumor-biopsy analyses based on combined mTOR-pathway biomarkers (and combined NGS and IHC assessments) could potentially provide treatment-informative stratification for particular cancer types. $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); Jean-François Laes1, Sebastien Sauvage1 and Gregori Ghitti1 1OncoDNA SA, 6041 Gosselies, Belgium Correspondence to: Jean-François Laes, email: jf.laes@oncodna.com Keywords: cancer, biomarker, tumor stratification, mTor activation, PIK3CA activation and PTEN loss Received: August 16, 2016 Accepted: September 01, 2017 Published:


  • Stratification of tumors based on mTOR-pathway biomarkers.

    by Jean-Francois Laes, S Bastien Sauvage, Gregori Ghitti

    E23097 Background: The mTOR pathway is often activated in human cancers. In this study, a total of 538 samples representing 40 different cancer types were analysed to evaluate the relationship between mTOR pathway activity and mutations in the upstream genes PIK3CA and PTEN. Methods: FFPE samples were analysed both by NGS (PIK3CA, PTEN, mTOR, TSC1, TSC2) and IHC (PTEN, 4pEBP1). Results: Overall, mTOR-pathway activation was identified in 83% of the samples, functional mutations were found in either or both PIK3CA and PTEN genes in 32% of the samples but there was no signification association between them. However when separating samples by cancer types, potential associations were identified. One example is the combination of PIK3CA activating mutation and PTEN loss of function which was associated with mTOR-pathway activation, most notably in the breast-cancer samples. Such combination has been associated with poor outcomes to some treatments (trastuzumab). Conclusions: In conclusion, our results show that stratification of tumors using the combination of mTOR-pathway biomarkers (and combined NGS and IHC technologies in their assessment) is potentially more informative than using a single biomarker to select the best treatment.